scholarly journals Continuous, Large-Volume Hydrodissection to Protect Delicate Structures around the Thyroid throughout the Radiofrequency Ablation Procedure

2021 ◽  
pp. 1-9
Author(s):  
Yanping Ma ◽  
Tao Wu ◽  
Zhicheng Yao ◽  
Bowen Zheng ◽  
Lei Tan ◽  
...  

<b><i>Introduction:</i></b> Small-volume hydrodissection liquid dissipates rapidly and confers only short-term protection during radiofrequency ablation (RFA) of benign thyroid nodules. The aim of this study was to establish a safe method for continuous, large-volume hydrodissection. <b><i>Methods:</i></b> A long needle was inserted and positioned outside the thyroid capsule; 5% glucose was injected to maintain a 3- to 5-mm continuous safety buffer. From October 2015 to July 2020, 166 patients underwent hydrodissection with different volumes, and ablation efficacy and complications associated with different liquid volumes (≤40 mL vs. &#x3e;40 mL) were compared at 1-month postprocedure. Moreover, 20 mL liquid (equivalent to 250 mL in the human body) was injected around the thyroid of a rhesus monkey, after which CT scans were used to visualize the liquid’s fate and verify its safety. <b><i>Results:</i></b> The 51 patients with 10–40 mL injections and 116 patients with larger injections (45–450 mL) showed similar complete ablation rates (88.46% vs. 90.44%, <i>p</i> = 0.582), comparable 6-month VRR (82.79% vs. 76.62%, <i>p</i> = 0.079), and complication incidences, although the latter group had larger nodules (9.11 mL vs. 13.79 mL, <i>p</i> = 0.003), more energy delivered (3.44 kcal vs. 6.04 kcal, <i>p</i> &#x3c; 0.001), and longer operation times (51.37 min vs. 69.2 min, <i>p</i> &#x3c; 0.001). In the animal experiment, the 20 mL of liquid diffused quickly (within 10 min) from the vicinity of the thyroid to the mediastinum and retropharyngeal space. It was observed in the kidneys at 10 min and disappeared from the neck and chest space by 24 h. <b><i>Conclusions:</i></b> Continuous, large-volume hydrodissection can protect the delicate structures around the thyroid throughout the RFA procedure and might be beneficial in large thyroid nodule ablation.

2018 ◽  
Author(s):  
Raul Rodriguez Escobedo ◽  
Silvia Gonzalez Martinez ◽  
Fernando Garcia Urruzola ◽  
Soraya Lanes Iglesias ◽  
Alicia Martin Nieto ◽  
...  

2021 ◽  
Author(s):  
Peter Horwich ◽  
Brent A. Chang ◽  
Ameya A. Asarkar ◽  
Gregory W. Randolph ◽  
Cherie‐Ann O. Nathan

2020 ◽  
Vol 37 (1) ◽  
pp. 742-748
Author(s):  
Yangsean Choi ◽  
So-Lyung Jung ◽  
Jinhee Jang ◽  
Na-Young Shin ◽  
Kook-Jin Ahn ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Lin Yan ◽  
Mingbo Zhang ◽  
Fang Xie ◽  
Jun Ma ◽  
Jing Xiao ◽  
...  

Abstract Background Radiofrequency ablation (RFA) is recommended for the treatment of benign thyroid nodules. However, data on the clinical role of RFA for benign thyroid nodules in patients with history of thyroid lobectomy are insufficient. The purpose of this study was to evaluate the efficacy and safety of radiofrequency ablation (RFA) for benign thyroid nodules in patients who had previously undergoing thyroid lobectomy. Methods From May 2015 to October 2018, a total of 20 patients (19 females, 1 male, mean age 49.50 ± 14.26 years, range 22–74 years) with 20 benign thyroid nodules (mean volume 15.04 ± 21.17 ml, range 0.40–69.67 ml) who had undergone previous thyroid lobectomy were included in this retrospective study. Patients were followed up at 3, 6, 12 months after RFA and every 12 months thereafter by ultrasound, clinical evaluation and thyroid function. Volume, volume reduction rate (VRR), symptom score and cosmetic score were evaluated. Results During the mean follow-up time of 21.24 ± 16.41 months, the mean nodule volume decreased significantly from 15.04 ± 21.17 ml to 1.29 ± 1.17 ml (P = 0.018) with a mean VRR of 85.41 ± 12.17%. Therapeutic success was achieved in a single session for all thyroid nodules. The symptom score (P = 0.001) and cosmetic score (P = 0.001) were both significantly reduced at the last follow-up. The levels of free triiodothyronine (fT3), free thyroxine (fT4) and thyroid stimulating hormone were not significantly different at the last follow-up from those prior to treatment (all P > 0.05). No life-threatening complications or sequelae occurred after RFA. Conclusions As a minimally invasive modality, RFA was a safe, effective, and thyroid function-preserving option for patients with symptomatic benign thyroid nodules after a previous lobectomy.


2015 ◽  
Vol 8 (2) ◽  
pp. 183 ◽  
Author(s):  
Tae Hyun Kim ◽  
Se-Mi Kim ◽  
Ah-Lon Jung ◽  
Seung Ki Moon ◽  
Dong Hoon Yang ◽  
...  

2017 ◽  
Vol Special iss (5) ◽  
Author(s):  
Hojat Ebrahiminik ◽  
Ali Mosaddegh khah ◽  
Ahmadreza Soroush ◽  
Narges Fadaei ◽  
Babak Shekarchi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document